SCHEMBL502000

SCHEMBL502000

CCCCCCCCCCCCCCCC=CC([O])=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 3/20 0.57
PPARG P37231 4/20 0.56
PPARA Q07869 4/20 0.56
TERT O14746 3/20 0.55
PTPN1 P18031 3/20 0.55
CYP1A2 P05177 2/20 0.55
MAPT P10636 2/20 0.55
CYP2C19 P33261 2/20 0.55
BLM P54132 2/20 0.55
HSD17B10 Q99714 2/20 0.55
FABP4 P15090 2/20 0.55
FAAH O00519 2/20 0.55
KMT2A Q03164 2/20 0.55
PPARD Q03181 2/20 0.55
GMNN O75496 1/20 0.55
USP2 O75604 1/20 0.55
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.55
CYP2C9 P11712 1/20 0.55
ALOX15 P16050 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7552771 1.00 FABP3 (0.57) FABP3PPARGPPARATERTPTPN1
SCHEMBL6424763 1.00 FABP3 (0.57) FABP3PPARGPPARATERTPTPN1
SCHEMBL4200342 1.00 FABP3 (0.57) FABP3PPARGPPARATERTPTPN1
SCHEMBL7552935 1.00 FABP3 (0.57) FABP3PPARGPPARATERTPTPN1
SCHEMBL5066940 1.00 FABP3 (0.57) FABP3PPARGPPARATERTPTPN1
SCHEMBL4200339 1.00 FABP3 (0.57) FABP3PPARGPPARATERTPTPN1
SCHEMBL6424766 1.00 FABP3 (0.57) FABP3PPARGPPARATERTPTPN1
SCHEMBL4203778 1.00 FABP3 (0.57) FABP3PPARGPPARATERTPTPN1
SCHEMBL501714 1.00 FABP3 (0.57) FABP3PPARGPPARATERTPTPN1
SCHEMBL7781593 1.00 FABP3 (0.57) FABP3PPARGPPARATERTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112237628-A EBV-targeted LMP2-mRNA nano vaccine 四川大学华西医院 2021-01-19 CN claimed
CN-112180079-A Stable liposome particles and application thereof in immunoturbidimetric assay 上海睿康生物科技有限公司 2021-01-05 CN claimed
EP-1551370-A1 AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN IDEA AG (DE) 2005-07-13 EP claimed
WO-2004032900-A1 AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN IDEA AG (DE) 2004-04-22 WO claimed
WO-2023190166-A1 CATIONIC LIPID HAVING DISULFIDE BOND, LIPID MEMBRANE STRUCTURE INCLUDING SAME, NUCLEIC ACID INTRODUCTION AGENT AND PHARMACEUTICAL COMPOSITION CONTAINING ANY ONE OF SAME, METHOD FOR INTRODUCING NUCLEIC ACID INTO CELL OR TARGET CELL, AND METHOD FOR PRODUCING CELLULAR PHARMACEUTICAL 日油株式会社 2023-10-05 WO disclosed
WO-2023190170-A1 METHOD FOR PRODUCING NUCLEIC ACID-ENCAPSULATED LIPID NANOPARTICLES, METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITION CONTAINING SAID LIPID NANOPARTICLES, AND METHOD FOR INTRODUCING NUCLEIC ACID INTO CELL OR TARGET CELL 日油株式会社 2023-10-05 WO disclosed
CN-112237628-A EBV-targeted LMP2-mRNA nano vaccine 四川大学华西医院 2021-01-19 CN disclosed
CN-112180079-A Stable liposome particles and application thereof in immunoturbidimetric assay 上海睿康生物科技有限公司 2021-01-05 CN disclosed
US-8906279-B2 Manufacturing method of polarizing plate protective film, polarizing plate protective film, polarizing plate, and liquid crystal display device KONICA MINOLTA OPTO, INC. (JP) 2014-12-09 US disclosed
US-8569405-B2 Additive mixtures for styrenic polymers BASF SE (DE) 2013-10-29 US disclosed
US-8518302-B2 Stabilization of organic materials BASF SE (DE) 2013-08-27 US disclosed
US-20120088869-A1 STABILIZATION OF ORGANIC MATERIALS GERSTER MICHELE (CH) 2012-04-12 US disclosed
US-5369159-A Heat, oxidation and radiation resistance for polymers CIBA-GEIGY CORPORATION (US) 1994-11-29 US disclosed
US-5367008-A 3-(alkoxyphenyl)benzofuran-2-ones as stabilisers CIBA-GEIGY CORPORATION (US) 1994-11-22 US disclosed
US-5356966-A Stabilizing organic material against oxidative, thermal or light iinduced degradation CIBA-GEIGY CORPORATION (US) 1994-10-18 US disclosed
EP-0608198-A1 Cyclic diphenylacetonenitriles as stabilisers CIBA-GEIGY AG (CH) 1994-07-27 EP disclosed
EP-0591102-A1 3-(2-Acyloxyethoxyphenyl)benzofuran-2-ones as stabilizers CIBA-GEIGY AG (CH) 1994-04-06 EP disclosed
EP-0589839-A1 3-(Dihydrobenzofuran-5-yl)benzofuran-2-ones as stabilizers CIBA-GEIGY AG (CH) 1994-03-30 EP disclosed
US-5216052-A Useful for stabilization of synthetic polymers against oxidative, thermal and light-induced degradation CIBA-GEIGY CORPORATION (US) 1993-06-01 US disclosed
WO-1992003122-A1 PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS CEVC GREGOR (DE) 1992-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088869-A1 STABILIZATION OF ORGANIC MATERIALS LPO, AOX1, SOD1 FABP3 3633/4885PPARG 890/4885PPARA 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.